Clinical Trial Results: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating pembrolizumab with or without investigational agents as neoadjuvant therapy in stage III melanoma; results completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-08-27